Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-022/ENGOT-ov84/GOG-3103 maintenance study in platinum-sensitive recurrent ovarian cancer
jRCT2031240722Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Merck & Co. Primary endpoints: Part 1 safety and tolerability and Part 2 progression-free survival (PFS). Started Apr 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2031240722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240722.